According to the accounts, total income is likely to be over $20m for the year to June 15.
Probably $13-14m of that is from Chiesi in the form of cash reimbursement.
So the cash burn must not be far from being eliminated.
Add back the Chiesi cash to the $19m on the balance sheet at the half year gets you $33m cash.
Say that falls to $25m by the time costs and income align.
Then you have a Bronchitol royalty stream in Europe and the USA, plus LOXL2 and SSAO programs, plus their manufacturing capability, in for $3m.
Ann: Half Yearly Report and Accounts, page-9
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.1¢ |
Change
-0.002(4.65%) |
Mkt cap ! $59.04M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.3¢ | 4.0¢ | $70.51K | 1.739M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 741022 | 4.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.2¢ | 190142 | 1 |
View Market Depth
| Last trade - 11.38am 14/10/2024 (20 minute delay) ? |
| SNT (ASX) Chart |